FDA Delays Approval of Replimune’s Melanoma Therapy Despite Promising Trial Results
For now, the FDA has denied approval today of a new melanoma treatment developed by Replimune. The company’s lead drug...
Approval
GSK’s ViiV Healthcare Secures EU Approval for Vocabria Combination Therapy for HIV Treatment in Adolescents -January 31, 2025 at 07:33 am EST
Market Closed - London S.E. 11:35:16 2025-01-31 am EST 5-day change 1st Jan Change 1,405.00 GBX +0.21% +3.58% +4.34% January...
